Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

多发性骨髓瘤 医学 泊马度胺 来那度胺 耐火材料(行星科学) 内科学 Carfilzomib公司 肿瘤科 重症监护医学 生物 天体生物学
作者
Surbhi Sidana,Krina K. Patel,Lauren C. Peres,Radhika Bansal,Mehmet H. Kocoglu,Leyla Shune,Shebli Atrash,Kinaya Smith,Shonali Midha,Christopher Ferreri,Binod Dhakal,Danai Dima,Patrick Costello,Charlotte B Wagner,Ran Reshef,Hitomi Hosoya,Lekha Mikkilineni,Djordje Atanackovic,Saurabh Chhabra,Ricardo Parrondo
出处
期刊:Blood [Elsevier BV]
被引量:13
标识
DOI:10.1182/blood.2024025945
摘要

Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met CARTITUDE-1 trial eligibility criteria. Manufacturing failure rates at first attempt and overall were 6% and 1%, respectively. Median prior lines of therapy were 6. In treated patients (N=236), cytokine release syndrome was seen in 75% (>= grade 3: 5%), immune effector cell-associated neurotoxicity syndrome in 14% (>= grade 3: 4%), and delayed neurotoxicity in 10%. Best overall and >= CR rates were as follows: infused patients (N=236): 89% and 70%; patients receiving conforming CAR-T product (N=191) 94% and 74%; conforming CAR-T product with fludarabine/cyclophosphamide lymphodepletion (N=152): 95% and 76%, respectively. Non-relapse mortality was 10%, most commonly from infection. After median follow-up of 13 months from CAR-T, median progression-free survival (PFS) was not reached, with 12- month estimate being 68% (95% CI: 62-74%). High ferritin levels, high-risk cytogenetics, and extramedullary disease were independently associated with inferior PFS, with a signal for prior BCMA-TT (p=0.08). Second primary malignancies (SPMs) excluding non-melanoma skin cancers were seen in 5.5% and myeloid malignancies/acute leukemia in 1.7%. We observed a favorable efficacy profile of standard of care cilta-cel in RRMM despite more than half the patients not meeting CARTITUDE-1 eligibility criteria.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
王哈哈完成签到,获得积分10
刚刚
香蕉觅云应助人间不清醒采纳,获得30
2秒前
5秒前
6秒前
bzdjsmw完成签到 ,获得积分10
6秒前
WebCasa应助旦皋采纳,获得10
6秒前
路易斯完成签到,获得积分10
7秒前
颜愫发布了新的文献求助10
7秒前
萌萌完成签到,获得积分10
8秒前
研友_X89o6n完成签到,获得积分10
10秒前
Ther发布了新的文献求助10
12秒前
哈哈哈完成签到,获得积分10
13秒前
15秒前
诚心的初露完成签到,获得积分10
15秒前
lyb完成签到 ,获得积分10
17秒前
风中方盒完成签到,获得积分20
17秒前
布丁圆团完成签到,获得积分10
18秒前
yikeshu完成签到,获得积分10
18秒前
Zoe完成签到 ,获得积分10
19秒前
21秒前
星辰大海应助do0采纳,获得10
22秒前
tt完成签到 ,获得积分10
23秒前
浅辰完成签到,获得积分10
24秒前
大气萤完成签到,获得积分20
25秒前
25秒前
我ppp完成签到 ,获得积分10
25秒前
26秒前
易燃物品完成签到,获得积分10
26秒前
Hello应助Ther采纳,获得10
28秒前
CherylZhao完成签到,获得积分10
29秒前
Galato发布了新的文献求助10
30秒前
颜愫完成签到,获得积分10
30秒前
安详向日葵完成签到 ,获得积分10
31秒前
拼搏的白云完成签到,获得积分10
31秒前
852应助hhh采纳,获得10
31秒前
李白白白完成签到,获得积分10
31秒前
王手完成签到,获得积分10
31秒前
32秒前
一人完成签到,获得积分10
33秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029